In addition, the reduction in systemic inflammation in IPA-treated mice caused a reduction in neuroinflammation, resulting in a decrease in DAMPs in the brain, which may be another reason for the decrease in NLRP3 activation. This evidence concerns the gene NLRP3 and Ito hypomelanosis.